Cargando…

Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities

Dry eye (DE), especially severe DE (SDE), can cause ocular surface defects and reduce the patient's quality of life. Several clinical studies have shown that 0.1% cyclosporin A cationic emulsion (CsA CE) could decrease corneal damage. However, no experimental study has reported the effect of 0....

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Rujun, Li, Ying, Li, Lan, Kim, Jonghwa, Yoon, Hyeon Jeong, Yoon, Kyung Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515563/ https://www.ncbi.nlm.nih.gov/pubmed/34659509 http://dx.doi.org/10.3892/etm.2021.10797

Ejemplares similares

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney, Tatiana, et al.
Publicado: (2018)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye in Korea: A Prospective, Multicenter, Open-Label, Surveillance Study
por: Byun, Yong-Soo, et al.
Publicado: (2011)

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye
por: Park, Yuli, et al.
Publicado: (2017)

A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye
por: Hovanesian, John, et al.
Publicado: (2023)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian, Cynthia, et al.
Publicado: (2021)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease
por: Baudouin, Christophe, et al.
Publicado: (2017)

PERSIST: Physician’s Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
por: Mah, Francis, et al.
Publicado: (2012)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee, Michelle K, et al.
Publicado: (2017)

Cyclosporine (0.05%) Combined with Diclofenac Sodium Eye Drops for the Treatment of Dry Eye Disease
por: Bai, Run, et al.
Publicado: (2022)

A Randomized Study of the Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in Treatment of Moderate to Severe Dry Eye
por: Baudouin, Christophe, et al.
Publicado: (2017)

Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment
por: Geerling, Gerd, et al.
Publicado: (2022)

Assessment of the efficacy of 0.1% cyclosporine A cationic emulsion in the treatment of dry eye disease during COVID-19 pandemic
por: Stopyra, Wiktor
Publicado: (2023)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher, Karl G, et al.
Publicado: (2016)

Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
por: Park, Chang Hyun, et al.
Publicado: (2019)

Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery
por: Lee, Jang Hoon, et al.
Publicado: (2016)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural, Ece, et al.
Publicado: (2011)

Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation
por: Mullick, Ritika, et al.
Publicado: (2021)

A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome
por: Lee, Ji Eun, et al.
Publicado: (2022)

The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery
por: Karadag, Ayse Sevgi, et al.
Publicado: (2021)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella, Pierre-Jean, et al.
Publicado: (2018)

Retraction Note: Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
por: Park, Chang Hyun, et al.
Publicado: (2020)

Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis
por: Okumus, Seydi, et al.
Publicado: (2012)

Conjunctival T Cell Profile in Allogeneic Hematopoietic Stem Cell Transplant Patients after Instilling Topical Cyclosporine-A 0.1% Cationic Emulsion
por: Tong, Louis, et al.
Publicado: (2023)

Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial
por: Peng, Wenyan, et al.
Publicado: (2022)

Cellulose Acetate Phthalate-Based pH-Responsive Cyclosporine A-Loaded Contact Lens for the Treatment of Dry Eye
por: Kim, Jonghwa, et al.
Publicado: (2023)

A randomized controlled trial involving college student: Comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the Treatment of Dry Eye
por: Xu, Wenhao, et al.
Publicado: (2023)

Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study
por: Chen, Di, et al.
Publicado: (2019)

Retrospective Review on the Use of Topical Cyclosporin A 0.05% for Paediatric Allergic Conjunctivitis in Hong Kong Chinese
por: Wu, Macy M. S., et al.
Publicado: (2014)

Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children
por: Chatterjee, Arkendu, et al.
Publicado: (2019)

Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial
por: Rao, A Tarakeswara, et al.
Publicado: (2023)

Relationship between ocular surface temperature and 0.1% cyclosporine a in dry eye syndrome with meibomian gland dysfunction
por: Lee, Donghun, et al.
Publicado: (2023)

Effectiveness of Topical Cyclosporin-A 0.1% Compared to Combined Topical Cyclosporin-A 0.1% with Topical Sodium Hyaluronate on Interleukin-6 Levels in the Tears of Patients with Dry Eye Disease
por: Priani, Desti, et al.
Publicado: (2023)

Comparison of Pterygium Recurrence with and without Using Postsurgical Topical Cyclosporin A 0.05%: A Randomized Clinical Trial
por: Alizadeh, Yousef, et al.
Publicado: (2022)

Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients
por: Stonecipher, Karl G, et al.
Publicado: (2013)

Comparison of 0.1%, 0.18%, and 0.3% Hyaluronic Acid Eye Drops in the Treatment of Experimental Dry Eye
por: You, In Cheon, et al.
Publicado: (2018)

A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops
por: Napoli, Pietro Emanuele, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_arf6qb3k181nv4h7pi2adejm46